Compare
Mangoceuticals, Inc. vs BioRestorative Therapies, Inc. vs Cryo Cell International Inc vs Viemed Healthcare, Inc.
| Latest fiscal year | Mangoceuticals, Inc. MGRX | BioRestorative Therapies, Inc. BRTX | Cryo Cell International Inc CCEL | Viemed Healthcare, Inc. VMD |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-11-30 | 2025-12-31 |
| Revenue | $456.0K | $359.7K | $31.57M | $270.28M |
| Revenue growth (YoY) | -26.0% | -10.3% | -1.3% | +20.5% |
| Gross margin | 54.9% | 93.4% | 76.6% (computed) | 57.5% |
| Operating margin | n/m | n/m | 1.5% | 8.5% |
| Net margin | n/m | n/m | -7.7% | 5.5% |
| Net income | -$20.64M | -$14.24M | -$2.43M | $14.93M |
| EPS (Diluted) | -$2.17 | -$1.58 | -$0.30 | $0.37 |
| Operating cash flow | -$5.85M | -$10.79M | $5.48M | $51.92M |
| Free cash flow | n/a | -$10.91M | $5.25M | $11.93M |
| Cash & equivalents | $1.49M | $1.51M | $319.0K | $13.50M |
| Total assets | $16.09M | $4.08M | $61.73M | $199.15M |
| Total liabilities | $890.6K | n/a | $80.33M | $55.63M |
| Shareholders' equity | $15.20M | $356.7K | -$18.61M | $141.54M |
| Return on year-end equity | -135.8% | n/m | n/a | 10.6% |
| Shares outstanding | 15.89M | 8.88M | 8.06M | 38.02M |
Revenue, most recent five fiscal years
| Fiscal year | Mangoceuticals, Inc. | BioRestorative Therapies, Inc. | Cryo Cell International Inc | Viemed Healthcare, Inc. |
|---|---|---|---|---|
| Latest | $456.0K Ended 2025-12-31 | $359.7K Ended 2025-12-31 | $31.57M Ended 2025-11-30 | $270.28M Ended 2025-12-31 |
| 1 year earlier | $615.9K Ended 2024-12-31 | $401.0K Ended 2024-12-31 | $31.99M Ended 2024-11-30 | $224.26M Ended 2024-12-31 |
| 2 years earlier | $731.5K Ended 2023-12-31 | $145.8K Ended 2023-12-31 | $31.34M Ended 2023-11-30 | $183.01M Ended 2023-12-31 |
| 3 years earlier | $8.9K Ended 2022-12-31 | $119.8K Ended 2022-12-31 | $30.34M Ended 2022-11-30 | $138.83M Ended 2022-12-31 |
| 4 years earlier | n/a | $46.0K Ended 2021-12-31 | $28.88M Ended 2021-11-30 | $117.06M Ended 2021-12-31 |